This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (10) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tambaki, A. P. Articles by Elisaf, M. Search for Related Content PubMed PubMed Citation Articles by Tambaki, A. P. Articles by Elisaf, M. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Blood Pressure Medicines Social Bookmarking                         What's this?

Effects of Antihypertensive and Hypolipidemic Drugs on Plasma and High-Density Lipoprotein-Associated Platelet Activating Factor-Acetylhydrolase Activity

Laboratory of Biochemistry, Department of Chemistry, Medical School, University of Ioannina, Greece

Evangelos Rizos, MD

Department of Internal Medicine, Medical School, University of Ioannina, Greece

Vasilis Tsimihodimos, MD

Department of Internal Medicine, Medical School, University of Ioannina, Greece

Alexandros D. Tselepis, MD, PhD

Laboratory of Biochemistry, Department of Chemistry, Medical School, University of Ioannina, Greece

Moses Elisaf, MD, FRSH

Department of Internal Medicine, Medical School, University of Ioannina, Greece

Background: Human plasma platelet activating factor acetylhydrolase (PAF-AH) is a phospholipase A₂ primarily associated with low-density lipoprotein (LDL). PAF-AH activity has also been found on high-density lipoprotein (HDL). Most of the clinical studies that have investigated the plasma levels of PAF-AH activity in cardiovascular disease have involved patients who were under treatment with various drugs, such as antihypertensive or hypolipidemic agents. However, the influence of these drugs on the enzyme activity has not been adequately studied.

Material and Methods: We evaluated the effects of representative antihypertensive and hypolipidemic drugs on the total plasma, as well as on the HDL-associated PAF-AH activity, in 121 patients with essential hypertension and in 90 patients with dyslipidemias of type IIA or type IIB. Serum lipids and enzymatic activities were determined at baseline and after 3 months of treatment.

Results: The administration of lacidipine (4 mg, n = 21), valsartan (80 mg, n = 26), indapamide (2.5 mg, n = 20), benazepril (20 mg, n = 20), or atenolol (50 mg, n = 34) did not affect either the total plasma- or the HDL-associated PAF-AH activity. In contrast, treatment with fluvastatin (40 mg, n = 50) or ciprofibrate (100 mg, n = 40) reduced by 25% plasma PAF-AH activity (P < .001) associated with a decrease in serum levels of total cholesterol and LDL-cholesterol (P < .001). Furthermore, ciprofibrate induced an increase by 26% in HDL-associated PAF-AH activity (P = .004) along with an increase in serum HDL-cholesterol levels (P = .02).

Conclusions: Among all types of drugs studied, only those that significantly affect lipid metabolism, such as statins and fibrates, significantly influence PAF-AH activity in human plasma.

Key Words: hypertension • dyslipidemia • lipoprotein • plasma activating factor acetylhydrolase

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 9, No. 2, 91-95 (2004)
DOI: 10.1177/107424840400900204


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. A. Gardner, E. C. Reichert, M. K. Topham, and D. M. Stafforini Identification of a Domain That Mediates Association of Platelet-activating Factor Acetylhydrolase with High Density Lipoprotein J. Biol. Chem., June 20, 2008; 283(25): 17099 - 17106. [Abstract] [Full Text] [PDF]

				V. G. Saougos, A. P. Tambaki, M. Kalogirou, M. Kostapanos, I. F. Gazi, R. L. Wolfert, M. Elisaf, and A. D. Tselepis Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A2 Arterioscler Thromb Vasc Biol, October 1, 2007; 27(10): 2236 - 2243. [Abstract] [Full Text] [PDF]

				A. Spirou, E. Rizos, E. N. Liberopoulos, N. Kolaitis, A. Achimastos, A. D. Tselepis, and M. Elisaf Effect of Barnidipine on Blood Pressure and Serum Metabolic Parameters in Patients With Essential Hypertension: A Pilot Study Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2006; 11(4): 256 - 261. [Abstract] [PDF]

				A. Zalewski, J. J. Nelson, L. Hegg, and C. Macphee Lp-PLA2: A New Kid on the Block Clin. Chem., September 1, 2006; 52(9): 1645 - 1650. [Abstract] [Full Text] [PDF]